molecules of the month

“compound 27”

oral ELOVL1 inhibitor for ALD, CNS penetrant

toxicities observed in higher species

internal HTS and LBDD

Journal of Medicinal Chemistry

Vertex Pharmaceuticals Inc.

Chemical structure of molecule compound 27 Vertex ELOVL1 inhibitor
1 min read

8. The Vertex ELOVL1 inhibitor, compound 27, is a potent (13 nM) CNS-penetrant compound that reduces very long chain fatty acid (VLCFA) levels in the CNS, which are believed to be pathological in the rare disease adrenoleukodystrophy (ALD). The starting point came from an HTS on compounds from an internal collection. The molecule demonstrated activity in patient fibroblasts, lymphocytes, and microglia, as well as PD in mouse models of ALD. Unfortunately, preclinical safety findings in the skin, eye, and CNS including irreversible corneal damage in rat as well as seizures and skin lesions in cyno are significant risks to further development. A comparison of the findings to genetic models and data suggests on-target safety liabilities. The Vertex team generously shares safety…

request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.

already a member? log in: